Targeted Diagnostics Paradigm Diagnostics offers the Paradigm Cancer Diagnostic (PCDx) using next generation sequencing to tailor treatments to individual tumor pathways, presenting an opportunity to partner with oncology clinics and comprehensive cancer centers seeking precision medicine tools.

Clinical Data Registry With IRB-approved Paradigm registry enabling data collection, sharing, and visualization, there is a potential upsell to institutions requiring data integration and analytics to support real-world evidence, outcomes research, and payer conversations.

Growth Financing Recent Series B activity and multiple funding rounds suggest investor interest and a growth trajectory; appeal to strategic investors or partners for co-development, expanded clinical programs, or regional market expansion deployments.

Early Stage Revenue Current revenue is under one million, indicating a window for scalable offerings, bundled diagnostic services, or tiered pricing with volume-based deployments to capture early adopter oncology practices and specialty centers.

Market Positioning In a landscape with larger competitors and varied company sizes, Paradigm can differentiate through physician education, streamlined integration with hospital IT systems, and value-based case studies demonstrating improved decision-making in cancer care.